FDA Grants Approval for Leucovorin Calcium Supplement Application
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Leucovorin Calcium submitted by Barr.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Supportive Care
Company: Barr
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Barr
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Barr's Leucovorin Calcium enhances their competitive position in the oncology supportive care market. This development necessitates a strategic assessment of market dynamics and pricing strategies among competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry strategies and sales performance of Leucovorin Calcium by Barr post-approval.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.